Shares of Bio-Techne Corp. rallied 5.67% to $63.03 Monday, on what proved to be an all-around favorable trading session for ...

Bio-Techne公司近日宣布，它以RNAscope™技术为基础，推出了RNA和蛋白质的共检测产品。 了解RNAscope技术及其在多个领域的应用>> Bio-Techne公司近日宣布，它以RNAscope™技术为基础，推出了RNA和蛋白质的共检测产品。RNAscope技术由Bio-Techne旗下品牌ACD开发，是一种先进的 ...

12月10日，Bio-Techne上海研发、生产和物流中心项目举行开幕仪式，闵行区委副书记、区长陈华文与Bio-Techne集团总裁兼首席执行官金・克尔德曼、执行副总裁兼首席财务官吉姆・希佩尔等共同见证仪式。 Bio-Techne是全球第一家将科研试剂产品进行商业化生产的公司 ...

Bio-Techne’s 21% return over the past six months has outpaced the S&P 500 by 10.9%, and its stock price has climbed to $62.36 ...

MINNEAPOLIS and TOLOCHENAZ, Switzerland, June 22, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the ...

Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne’s proprietary R&D Systems ...

Why Bio-Techne Is Back on Investors Radar Bio-Techne (TECH) has been drifting after a tough year, but recent gains over the past 3 months suggest investors are rethinking the story as growth and ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-releases-second-quarter-fiscal-2025-results-302368325.html ...

The latest price target for Bio-Techne (NASDAQ:TECH) was reported by Argus Research on November 20, 2025. The analyst firm set a price target for $68.00 expecting TECH to rise to within 12 months (a ...

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir ...

MINNEAPOLIS, Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate ...

Bio-Techne said yesterday it has agreed to acquire CyVek in a deal that could be worth up to $195 million depending on how milestones shake out over the next six years. The acquisition is Bio-Techne’s ...